Summary

Genetic testing for variants of inosine monophosphate dehydrogenase isoforms will not predict clinical response to mycophenolate mofetil (MMF) in the treatment of lupus nephritis. The Study of Mycophenolate Mofetil in Management of Patients with Lupus Nephritis [ALMS] demonstrated the efficacy of MMF for induction and maintenance of response in lupus nephritis, but response was not uniform, leading to a search for predictors of efficacy.